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Introduction
Herbs are defined as the plants used for flavoring, food, 
medicine, or perfume. Historically, herbs have been 
widely used as the origin of  modern pharmacotherapy 
1. Herbs have been utilized for thousands of  years in 
Asia and South America, and are enjoying more and 
more popularity in Europe and North America 2,3. The 
co-administration of  herbs has been reported to occur 
among 16% prescription drug users in the United States 
4. In the clinic, the major reasons for the increased 
utilization of  herbs in combination with prescribed 
drugs are that herbs have been always believed to be 
safe. 
Pharmacokinetics-based herbs-drug interactions appear 
inevitable clinically and strongly limit the utilization 
of  herbs. For example, patients received oral warfarin 
(Coumadin, DuPont Pharmaceuticals), 5mg daily, for 
the first 3 consecutive days duringweek 1. Beginning 
in week 2, patients were randomly assigned to receive 
either oral AG, 1.0 g, or placebo b. i. d. (= 2 g/day), 
for 3 consecutive weeks. During week 4, all patients 
again received oral warfarin, 5 mg daily, for the first 3 
consecutive days. The INR index significantly after 2  
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weeks of  ginseng administration, which was closely 
correlated with the reduced peak plasma level of  
warfarin 5. 
Zidovudine (AZT) is a nucleoside analog reverse-
transcriptase inhibitor (NRTI) to treat HIV/AIDS , 
and has been approved and prescribed under the name 
Retrovir 6. AZT has been demonstrated to undergo 
UDP-glucuronosyltransferase (UGT) 2B7-catalyzed 
glucuronidation elimination after its absorption into 
the serum 7. To date, many herbal components have 
been demonstrated to exhibit the inhibition towards the 
metabolism of  AZT, such as demethylzeylasteral and 
20(S)-protopanaxatriol (ppt) 7,8.
Baicalein is the hydrolyzed product and main effective 
substance basis of  baicalin which is a flavonoid isolated 
from Scutellariae radix, and has been demonstrated 
to exhibit various biochemical and pharmacological 
activities, including anti-inflammatory, anti-tumor, 
anti-allergic, and anti-oxidation effects 9,10. As a herbal 
component exhibiting many pharmacological activities, 
the co-exposure possibility between baicalein and AZT 
is very high. Therefore, the aim of  the present study 
was  to evaluate the inhibition potential of  baicalein 
towards the metabolism of  AZT. The inhibition kinetic 
type and parameter (Ki) were determined, and in vitro-in 
vivo extrapolation (IVIVE) was carried out.
Materials and Methods
Chemicals and reagents
3’-azido-3’-deoxythimidine (AZT), Tris-HCl, alam-
African Health sciences Vol 14 No. 1 March 2014
  
  Corresponding author:
  Ling-Ting Kong, 
  Yantaishan hospitalYantai,ShandongChina
  E-mail:konglingting123456@163.com
            173
ethicin and uridine 5’-diphosphoglucuronic acid (UD-
PGA) (trisodium salt) were purchased from Sigma-
Aldrich (St Louis, MO). Baicalein was purchased from 
the National Institute for the Control of  Pharmaceu-
tical and Biological Products (Beijing, China). Pooled 
human liver microsomes (HLMs) were purchased from 
BD Gentest (Woburn, MA). All other reagents were 
of  HPLC grade or of  the highest grade commercially 
available.
Inhibition evaluation of  HLMs-mediated AZT glucuronidation 
by baicalein
Baicalein was dissolved in methanol at 20 mmol/L as 
stock solution. The incubation mixture (200 μL total 
volume) contained HLMs (final concentration=0.5 
mg/mL), 5 mM UDPGA, 5 mM MgCl2, 50 mM Tris-
HCl buffer (pH=7.4), 50 μg/mg protein alamethicin, 
and AZT (the concentration is corresponding to the 
apparent Km value). The incubation time was 30 min. 
The mixture was kept on ice until it was centrifuged at 
20000 ×g for 10 min at 4 °C. Aliquots of  supernatants 
were transferred for HPLC analysis. For the analysis 
AZT glucuronidation, the HPLC column was eluted at 
1 mL/min with a mobile phase of  acetonitrile aqueous 
(v/v = 12:88). The aqueous phase contained 0.4 mL 
concentrated H3PO4 diluted to 1 L with water (pH 2.4). 
Ultraviolet detection was at 267 nm.
Furthermore, the reaction  was determined at multiple 
concentrations of  AZT and baicalein. Dixon plot and 
Lineweaver-Burk plot were used to determine the 
inhibition kinetic type, and the second plot was further 
employed to calculate the inhibition kinetic parameter 
(Ki).
Prediction of  in vivo baicalein-drug interaction magnitude
The baicalein-AZT interaction magnitude is affected 
by both in vitro inhibition kinetic parameters (Ki) and 
in vivo concentration of  baicalein. The most common 
equation for drug-drug interaction prediction was 
employed to predict the AUC alteration of  AZT caused 
by co-administration of  baicalein.
AUCi /AUC=1+[I]in vivo/Ki
The terms are defined as follows: AUCi /AUC is the 
predicted ratio of  in vivo exposure of  AZT with co-
administration of  baicalein vs. that in control situation. 
Ki is the in vitro reversible inhibition constant, [I]in vivo 
is the in vivo concentration of  baicalein. In this study, 
the maximum plasma concentration (Cmax) of  baicalein 
was used.
Results
The dose-dependent inhibition behaviour of  baicalein 
towards AZT glucuronidation was observed. The 
HLMs-catalyzed AZT glucuronidation activity was 
inhibited by -1.1%, 0.1%, 0.2%, 7.7%, 9.5%, 20.9%, 
40%, and 53.4% for 0.5, 1, 5, 10, 20, 40, 80, and 100 
μM of  baicalein (Fig. 1). 
Fig. 1 The concentration-dependent inhibition 
of  baicalein towards the metabolism of  zidovudine (AZT). The data point represents the mean of  duplicate 
experiment.
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Dixon plot was drawn using the 1/reaction velocity (v) 
versus the concentration of  baicalein, and Lineweaver-
Burk plot was drawn with the 1/reaction velocity (v) 
versus 1/the concentration of  AZT. For the inhibition 
of  baicalein towards the metabolism of  AZT, the 
intersection point was located in the second quadrant in 
Dixon plot (Fig. 2A), and the verticle axis in Lineweaver-
Burk plot (Fig. 2B).
Fig. 2 Determination of  inhibition kinetic type for baicalein’s inhibition towards the metabolism of  zidovudine 
(AZT). (A) Dixon plot for baicalein’s inhibition towards the metabolism of  zidovudine (AZT); (B) Lineweaver-
Burk plot for baicalein’s inhibition towards the metabolism of  zidovudine (AZT). The data point represents the 
mean of  duplicate experiment.
The second plot with the slopes from Lineweaver-Burk 
plot versus baicalein’s concentrations was performed to 
determine the inhibition parameter (Ki) to be 101.2 μM. 
The maximum concentration of  baicalein in plasma 
was reported to be approximately 100 μM after i.v. 
administration of  2.2 mg/kg or 5.5 mg/kg of  baicalein 
for rats 11. Using this value in combination the Ki value, 
the value of  AUCi/AUC was calculated to be 2.
Fig. 3 Calculation of  inhibition kinetic parameter (Ki) using the second plot drawn with the slopes from Lineweaver-
Burk versus the concentrations of  baicalein. 
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Discussion
Drug-metabolizing enzymes (DMEs)-based clinical 
drug-drug interaction (DDI) and herb-drug interaction 
(HDI) limited the utilization of  many clinical drugs and 
R&D process of  potential drugs. For example, the strong 
inhibition of  noscapine towards cytochrome P450 2C9 
and 3A4 strongly limited the utilization of  noscapine 
as an efficient antitussive drug and the development of  
this compound as a potential anti-tumor drug 12. The 
inhibition of  herbal components liquiritigenin and 
isoliquiritigenin towards the metabolism of  hypnotic 
agent propofol limited the co-utilization of  these two 
herbal components and propofol 13. 
The dose beyond the efficient concentration of  AZT 
can induce the genotoxicity and minimum cell death 14. 
AZT has a narrow therapeutic index, and slight alteration 
of  AZT concentration will exceed the minimal toxicity 
concentration of  AZT. The present study reported 
the AUCi/AUC value was 2 through in vitro-in vivo 
extrapolation (IVIVE) using the in vitro Ki value and 
in vivo concentration of  baicalein. This result can be 
affected by the following factors: 1) In vitro incubation 
factors:  previous literature has reported that the addition 
of  bovine serum albumin (BSA) can significantly cause 
the reduction of  Ki value for fluconazole inhibition of  
AZT glucuronidation by HLM 15. Therefore, the Ki value 
calculated in the present study might underestimate the 
baicalein-AZT interaction due to the lack of  BSA in 
our present incubation system. 2) In vivo factors: The 
present study using the in vivo concentration after i.v. 
adminstration of  single purified compound. When 
the administration route is different (e.g., oral gavage 
(p.o.), intraperitoneal injection (i.p.), etc.) or the herbs 
containing baicalein is given, the in vivo concentration 
of  baicalein might be different which can further 
complicate  the IVIVE results.
In conclusion, the baicalein-AZT interaction was 
indicated in the present study using in vitro inhibition 
experiment, which challenges the co-utilization of  AZT 
and baicalein or baicalein-containing herbs. 
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